JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Scope & Guideline
Fostering Collaboration in Pharmacological Studies
Introduction
Aims and Scopes
- Population Pharmacokinetics and Pharmacodynamics:
The journal emphasizes studies that utilize population pharmacokinetic and pharmacodynamic models to analyze drug behavior in diverse patient populations. This area is crucial for optimizing dosing regimens and understanding variability in drug responses. - Quantitative Systems Pharmacology (QSP):
QSP is a core focus, integrating biological systems modeling with pharmacokinetic and pharmacodynamic principles. This approach aids in predicting drug effects and interactions within complex biological systems, facilitating better drug development strategies. - Mechanistic and Semi-Mechanistic Modeling:
Research that develops mechanistic or semi-mechanistic models to describe drug action and interactions at various biological levels is prevalent. These models help elucidate the underlying biological processes affecting drug behavior. - Innovative Computational Techniques:
The journal showcases the application of advanced computational techniques, including machine learning and artificial intelligence, to pharmacokinetic and pharmacodynamic modeling, aiming to improve predictive accuracy and model efficiency. - Clinical Applications and Translational Research:
There is a strong emphasis on studies that bridge the gap between theoretical modeling and clinical application, particularly in areas such as oncology, rare diseases, and chronic conditions, enhancing the relevance of pharmacometric research to real-world clinical scenarios.
Trending and Emerging
- Integration of Machine Learning in Pharmacometrics:
There is a growing trend in utilizing machine learning techniques to enhance pharmacometric modeling. This includes applications in model selection, optimization, and predictive analytics, which are increasingly recognized for their potential to improve the robustness and efficiency of pharmacokinetic/pharmacodynamic analyses. - Focus on Rare Diseases and Pediatric Populations:
Research addressing pharmacokinetics and pharmacodynamics in rare diseases and pediatric populations is gaining momentum. This reflects a broader recognition of the need for tailored therapeutic strategies in these vulnerable groups. - Virtual Patient Models and Simulations:
The use of virtual patient models and simulations to predict drug responses and optimize treatment regimens is on the rise. These models allow for the exploration of various dosing scenarios and patient characteristics, enhancing translational research efforts. - Mechanistic Insights into Drug Action:
There is an increasing emphasis on studies that provide mechanistic insights into drug action and interactions, particularly through the development of semi-mechanistic and mechanistic models. This trend supports a deeper understanding of how drugs exert their effects at the biological level. - Emphasis on Quantitative Systems Pharmacology (QSP):
QSP is becoming a dominant theme, with a focus on integrating biological data with pharmacometric models to enhance the predictive capabilities of drug development processes. This approach is critical for improving the translation of preclinical findings to clinical outcomes.
Declining or Waning
- Traditional Compartmental Models:
There has been a noticeable decrease in the publication of studies exclusively relying on traditional compartmental models. As more sophisticated modeling approaches, such as physiologically-based pharmacokinetic (PBPK) models, gain traction, the relevance of simpler compartmental methods appears to be waning. - Basic Pharmacokinetic Studies:
Research focused solely on basic pharmacokinetic parameters without integrating pharmacodynamic aspects or clinical implications has decreased. The journal is increasingly favoring studies that combine pharmacokinetics with pharmacodynamics to provide a more comprehensive analysis. - Single-Agent Drug Studies:
The focus on studies examining the pharmacokinetics and pharmacodynamics of single-agent drugs is declining, as there is a growing interest in combination therapies and their complex interactions, particularly in oncology and chronic disease treatment. - Static Modeling Approaches:
Static models that do not account for variability or dynamic changes in drug effects over time are being replaced by more dynamic and flexible modeling approaches. This trend indicates a shift towards methods that better capture the complexities of drug action in real-world scenarios.
Similar Journals
CLINICAL PHARMACOLOGY & THERAPEUTICS
Transforming research into practice in clinical pharmacology.CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.
JOURNAL OF PHARMACY AND PHARMACOLOGY
Advancing pharmaceutical knowledge for a healthier tomorrow.Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
Fostering Knowledge in Veterinary Pharmacology and TherapeuticsJOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.
BRITISH JOURNAL OF PHARMACOLOGY
Pioneering insights into drug mechanisms and therapeutic innovations.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
ACTA PHARMACOLOGICA SINICA
Leading the Way in Pharmacological ResearchACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.
CLINICAL PHARMACOKINETICS
Exploring Clinical Insights in PharmacokineticsCLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.
International Journal of Pharmacology
Advancing the Frontiers of Pharmacological ResearchWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
Drug Design Development and Therapy
Pioneering the Future of Drug Design and Patient CareDrug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.
Drug Discoveries and Therapeutics
Advancing drug discovery for a healthier tomorrow.Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.
CURRENT OPINION IN PHARMACOLOGY
Shaping Tomorrow's Therapeutics TodayCurrent Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.